Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021
About Hypertrophic Cardiomyopathy Therapeutics
HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.
Technavio’s analysts forecast the global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021
Technavio recognizes the following companies as the key players in the global hypertrophic cardiomyopathy therapeutics market: AstraZeneca, Merck, Pfizer, and Sanofi
Other Prominent Vendors in the market are: Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from Technavio’s team said: “One trend in market is development of TBI. HCM is a complex genetic disorder, which requires an integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that can integrate and analyze these heterogeneous features are being developed in order to enhance the clinical guidelines for treatment and prevention of HCM and are named as TBI. TBI is a computational approach, which focuses on the integration and analysis of bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source, which not only performs data integration but also improves data representation. This will be done by using tools such as ontology and controlled vocabulary, as they provide a standard way for representation of data. These vocabulary sources are references that are accepted by specific user community like Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT).”
According to the report, one driver in market is increasing cases of HF. HCM is an extended form of a diastolic HF when the heart fails to perform its functions normally. The diastolic HF occurs when the lower left chamber or the LV is not filled properly with blood during the diastolic phase. Therefore, the amount of pumped blood is less than the normal. Similarly, in HCM, the increasing myocardium size results in smaller LV cavity size accompanied by impairment of blood flow. This leads to the common symptoms of both HCM and HF such as dyspnoea, angina, palpitations, syncope, and presyncope. Hence, the drug development for relieving the symptoms of HF benefits the global HCM therapeutics market as well. As per the CDC, more than five million people are living with HF in the US, and about half of the affected population succumb within five years of diagnosis. However, the deaths due to HF have significantly declined in the past few years due to improved therapies to treat the disease. However, the risk of developing HF continues to rise with the increasing population. This risk-factor has further triggered R&D for newer drugs, which can be repurposed for the diagnosis and treatment of HCM. The traditional HCM drug market has a long history of repurposed drugs for its prevention and cure. There are many drugs belonging to drug classes such as beta-adrenergic blockers, calcium channel blockers, and antiarrhythmic, which were originally developed for the treatment and prevention of HF and are now being employed in the treatment of HCM.
Further, the report states that one challenge in market is expensive serial screenings. Individuals with HCM may be asymptomatic or may complain of mild chest pain; CHF symptoms; or syncope, which is the temporary loss of consciousness due to fall in BP. The morphologic diagnosis is characterized by the presence of hypertrophied myocardium and non-dilated LV in the absence of other cardiac diseases that are capable of causing myocardium hypertrophy of more than 15 mm in an adult patient or equivalent to relative body surface area in children. The serial screening for evaluation of HCM includes two-dimensional echocardiography ($1,500), 24-hour ambulatory (Holter) electrocardiographic monitoring, 12-lead ECG, CMR, and TTE ($2,000) and evaluation by a cardiologist at an experienced center. These tests are not only time consuming but also very expensive and may pose a financial burden on an individual's family, thereby increasing anxiety and stress for the family.
AstraZeneca, Merck, Pfizer, Sanofi, Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook